MDxHealth Licenses Prognostic Prostate Cancer Biomarker From Philips

The agreement will enable MDxHealth to prepare the launch of its tissue-based InformMDx test for prostate cancer as the test will utilize the PDE4D7 biomarker to stratify patients according to their risk of disease progression and the development of secondary tumors.

Source: https://www.genomeweb.com/business-news/mdxhealth-licenses-prognostic-prostate-cancer-biomarker-philips?utm_source=Sailthru&utm_medium=email&utm_campaign=GWDN%20Wed%20AM%20-%20PERSONALIZED%202018-06-06&utm_term=GWDN%20Personalize%20Test